Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBT Margin (2016 - 2025)

Historic EBT Margin for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to 19.8%.

  • Anaptysbio's EBT Margin rose 1292400.0% to 19.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 55.86%, marking a year-over-year increase of 2338800.0%. This contributed to the annual value of 159.1% for FY2024, which is 7945800.0% up from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's EBT Margin is 19.8%, which was up 1292400.0% from 173.34% recorded in Q2 2025.
  • Anaptysbio's EBT Margin's 5-year high stood at 19.8% during Q3 2025, with a 5-year trough of 3237.84% in Q1 2022.
  • In the last 5 years, Anaptysbio's EBT Margin had a median value of 442.68% in 2022 and averaged 971.76%.
  • As far as peak fluctuations go, Anaptysbio's EBT Margin plummeted by -31311500bps in 2021, and later soared by 26323900bps in 2022.
  • Over the past 5 years, Anaptysbio's EBT Margin (Quarter) stood at 3075.07% in 2021, then soared by 86bps to 442.68% in 2022, then dropped by -6bps to 468.8% in 2023, then surged by 81bps to 87.16% in 2024, then surged by 123bps to 19.8% in 2025.
  • Its EBT Margin stands at 19.8% for Q3 2025, versus 173.34% for Q2 2025 and 141.46% for Q1 2025.